Targeted Drugs Shrank a Rare Brain Tumor in 5 Patients
Original title: Neoadjuvant Treatment of BRAFV600E Papillary Craniopharyngiomas: A Case Series.
How far along is this research?
- Lab cells
- Animals
- Review
- Tested in people
This was tested in people. That is the most reliable kind of research we share.
This was a small look back at 5 patients, not a real trial.
The short version
Five people with a rare brain tumor took targeted drugs, and their tumors got much smaller.
What was studied. Doctors looked back at records for 5 patients with a rare brain tumor. The tumor type is called papillary craniopharyngioma, and each one had a gene change called BRAFV600E. Doctors took a small tissue sample through a thin scope, then gave BRAF: A gene in a pathway that tells cells to divide. Some tumors carry a change in it. There are drugs made to target that change, so your team may test for it. See the glossary/MEK inhibitor drugs.
What they found. All 5 patients got at least 1 cycle of the drugs. Some had just 1 cycle and some had as many as 16. The tumors shrank by 97.8% on average. No patient lost hormone function. Two patients had vision problems at the start, and their vision got better. Two patients chose radiation after 5 cycles.
What this means, and what it doesn't
What it could mean: For this one rare tumor type, drugs may shrink the tumor a lot. In this small group, no one needed more surgery. Vision improved for two people, and hormone function held steady. Doctors may discuss this path with some patients who have this exact gene change.
What it doesn't mean: This was a small look back at only 5 patients. There was no comparison group, so this is not proof. It is not a cure, and it is early in the research. It only applies to this rare tumor type with the BRAFV600E gene change. Bigger studies are needed before this becomes normal care everywhere.
Source: PubMed, October 14, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.